174,061 Shares in Halozyme Therapeutics, Inc. $HALO Purchased by The Manufacturers Life Insurance Company

Key Points

• The Manufacturers Life Insurance Company purchased 174,061 Halozyme shares worth approximately $13.6 million, while institutional investors collectively own 97.79% of the company.
• Analysts remain broadly bullish: nine rate HALO a Buy, with an average rating of “Moderate Buy” and an average price target of $91.20; several firms recently raised their targets to as high as $115.
• Halozyme reported strong quarterly results, posting $2.28 in EPS and $481 million in revenue, up 47.7% year over year and above analyst expectations. However, insiders sold 64,103 shares worth $5.2 million over the past three months.

The Manufacturers Life Insurance Company bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 174,061 shares of the biopharmaceutical company's stock, valued at approximately $13,624,000. The Manufacturers Life Insurance Company owned 0.15% of Halozyme Therapeutics at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. MidFirst Bank purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at approximately $27,000. Larson Financial Group LLC lifted its holdings in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 343 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Halozyme Therapeutics in the second quarter worth approximately $28,000. Measured Wealth Private Client Group LLC grew its position in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 124 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Halozyme Therapeutics during the second quarter worth $30,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on HALO. HC Wainwright upped their price target on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a "buy" rating in a research note on Friday, August 7th. TD Cowen raised their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Leerink Partners upgraded shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $83.00 to $110.00 in a report on Friday, August 7th. Citizens Jmp upped their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research report on Friday, August 7th. Finally, UBS Group reaffirmed a "buy" rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $91.20.

Insider Transactions at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director owned 14,462 shares of the company's stock, valued at $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 64,103 shares of company stock valued at $5,226,496. Insiders own 2.50% of the company's stock.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $105.35 on Friday. The firm has a market cap of $11.96 billion, a PE ratio of 31.45, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $109.66. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company's 50 day moving average is $87.01 and its two-hundred day moving average is $74.78.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million during the quarter, compared to analysts' expectations of $402.28 million. During the same quarter last year, the company posted $1.54 EPS. The firm's revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source